Literature DB >> 1205026

Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients.

C Servo, E Pitkänen.   

Abstract

Cerebrospinal fluid (CSF) or CSF and plasma levels of sorbitol, 1,5-anhydroglucitol and myoinositol of diabetic and non-diabetic patients with normal kidney function and of diabetic and non-diabetic patients with impaired kidney function were measured by gas-liquid chromatography. The CSF sorbitol level correlated with the plasma glucose level (p less than or equal to 0.05) in diabetic patients with normal kidney function, having received insulin for less than 12 months. The correlation between CSF sorbitol and plasma glucose levels in patients not dependent on insulin was not significant. Sorbitol was not detected in the plasma. The highest sorbitol levels in CSF were seen in insulin-dependent diabetic patients with impaired kidney function. No rise was seen in non-diabetic uremia. 1,5-anhydroglucitol, normally present in plasma, was absent from CSF and plasma in diabetic patients receiving insulin. In non-diabetic uremic patients, 1,5-anhydroglucitol levels in CSF and plasma were lower than in healthy subjects, but htere was no correlation with plasma glucose levels. The myoinositol level was higher in CSF than in the plasma of both non-diabetic and diabetic patients with normal kidney function. Both plasma and CSF levels were significantly (p less than 0.001) elevated in diabetic as well as in non-diabetic uremic patients, the plasma myoinositol increasing relatively more than the CSF levels. The elevation of plasma myoinositol correlated with the elevation of plasma creatinine and thus also with the impairment of kidney function. Plasma and CSF myoinositol levels were not influenced by the plasma glucose level.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1205026     DOI: 10.1007/bf01222109

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  The renal excretion of inositol in normal and diabetic human beings.

Authors:  W H DAUGHADAY; J LARNER
Journal:  J Clin Invest       Date:  1954-03       Impact factor: 14.808

2.  The stimulus-secretion coupling of glucose-induced insulin release. Sorbitol metabolism in isolated islets.

Authors:  W J Malaisse; A Sener; M Mahy
Journal:  Eur J Biochem       Date:  1974-09-01

3.  Hypermyoinositolemic polyneuropathy in rats. A possible mechanism for uremic polyneuropathy.

Authors:  P V DeJesus; R S Clements; A I Winegrad
Journal:  J Neurol Sci       Date:  1974-03       Impact factor: 3.181

4.  Raised plasma-myoinositol levels in uraemia and experimental neuropathy.

Authors:  R S Clements; P V DeJesus; A I Winegrad
Journal:  Lancet       Date:  1973-05-26       Impact factor: 79.321

Review 5.  The sorbitol pathway and the complications of diabetes.

Authors:  K H Gabbay
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

6.  Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissues.

Authors:  J D Ward; R W Baker; B H Davis
Journal:  Diabetes       Date:  1972-12       Impact factor: 9.461

7.  Cerebrospinal fluid polyols in patients with diabetes mellitus.

Authors:  E Pitkänen; C Servo
Journal:  Clin Chim Acta       Date:  1973-03-30       Impact factor: 3.786

8.  Occurrence of I,5-anhydroglucitol in human cerebrospinal fluid.

Authors:  E Pitkänen
Journal:  Clin Chim Acta       Date:  1973-10-12       Impact factor: 3.786

9.  The serum polyol pattern and the urinary polyol excretion in diabetic and in uremic patients.

Authors:  E Pitkänen
Journal:  Clin Chim Acta       Date:  1972-04       Impact factor: 3.786

  9 in total
  13 in total

1.  Renal tubular reabsorption of 1,5-anhydro-D-glucitol and D-mannose in vivo in the rat.

Authors:  E Pitkänen; O M Pitkänen
Journal:  Pflugers Arch       Date:  1992-03       Impact factor: 3.657

2.  Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients.

Authors:  T Yamanouchi; H Akanuma; T Nakamura; I Akaoka; Y Akanuma
Journal:  Diabetologia       Date:  1988-01       Impact factor: 10.122

3.  Clinical application of the serum 1,5-anhydroglucitol assay method using glucose 3-dehydrogenase.

Authors:  Tetsuro Hamafuji; Wakako Tsugawa; Koji Sode
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

4.  Purification of a marine bacterial glucose dehydrogenase from Cytophaga marinoflava and its application for measurement of 1,5-anhydro-D-glucitol.

Authors:  W Tsugawa; S Horiuchi; M Tanaka; H Wake; K Sode
Journal:  Appl Biochem Biotechnol       Date:  1996-03       Impact factor: 2.926

5.  The elimination of 1,5-anhydroglucitol administered to rats.

Authors:  E Pitkänen; O Pitkänen
Journal:  Experientia       Date:  1984-05-15

6.  Conditional synthesis and utilization of 1,5-anhydroglucitol in Escherichia coli.

Authors:  Y Shiga; H Mizuno; H Akanuma
Journal:  J Bacteriol       Date:  1993-11       Impact factor: 3.490

7.  Plasma 1,5-anhydroglucitol in experimental galactosemia in the rat.

Authors:  E Pitkänen; O M Pitkänen
Journal:  Experientia       Date:  1990-01-15

8.  Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.

Authors:  William T Regenold; K Calvin Hisley; Pornima Phatak; Christopher M Marano; Abraham Obuchowski; David M Lefkowitz; Amritpal Sassan; Sameer Ohri; Tony L Phillips; Narveen Dosanjh; Robert R Conley; Rao Gullapalli
Journal:  Bipolar Disord       Date:  2008-11       Impact factor: 6.744

9.  Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients.

Authors:  Y Akanuma; M Morita; N Fukuzawa; T Yamanouchi; H Akanuma
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

10.  Localization of aldose reductase and sorbitol dehydrogenase in the nervous system of normal and diabetic rats.

Authors:  S E Orosz; S F Townsend; P A Tornheim; C M Brownscheidle
Journal:  Acta Diabetol Lat       Date:  1981 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.